ELN and cancer: A follow-up study of 631 CRC resections found elastin-detected VI to be associated with a decrease in 5-year cancer-specific survival from 92 to 67% in node-negative disease (T1-4,N0) and from 79 to 42% in node positive disease (T1-4,N1/2).